The present invention relates to a nanoplasmonic biosensor capable of label-free multiplex detection of disease markers in blood with high selectivity and sensitivity and a method for detecting disease markers using the nanoplasmonic biosensor. The nanoplasmonic biosensor of the present invention enables label-free multiplex detection of miRNAs as disease markers in blood with high selectivity and sensitivity. Therefore, the nanoplasmonic biosensor of the present invention can be effectively used for the diagnosis of miRNA-related diseases and clinical applications.

The present invention relates to a nanoplasmonic biosensor capable of label-free multiplex detection of disease markers in blood with high selectivity and sensitivity and a method for detecting disease markers using the nanoplasmonic biosensor. The nanoplasmonic biosensor of the present invention enables label-free multiplex detection of miRNAs as disease markers in blood with high selectivity and sensitivity. Therefore, the nanoplasmonic biosensor of the present invention can be effectively used for the diagnosis of miRNA-related diseases and clinical applications.

The present invention relates to a nanoplasmonic biosensor capable of label-free multiplex detection of disease markers in blood with high selectivity and sensitivity and a method for detecting disease markers using the nanoplasmonic biosensor. The nanoplasmonic biosensor of the present invention enables label-free multiplex detection of miRNAs as disease markers in blood with high selectivity and sensitivity. Therefore, the nanoplasmonic biosensor of the present invention can be effectively used for the diagnosis of miRNA-related diseases and clinical applications.

Provided herein is a method of concentrating a tethering complex in a region of an amphiphilic layer, such as a lipid membrane. Also provided herein are methods of assembling a tethering complex; methods of concentrating an analyte in the region of a detector; amphiphilic layers; and arrays and devices for use in the disclosed methods.

Provided herein is a method of concentrating a tethering complex in a region of an amphiphilic layer, such as a lipid membrane. Also provided herein are methods of assembling a tethering complex; methods of concentrating an analyte in the region of a detector; amphiphilic layers; and arrays and devices for use in the disclosed methods.

Described herein are nucleic acid-based electrochemical proximity assays (ECPAs) for sample quantification. The invention may also include a biosensor with a sensing mechanism that uses a pair of aptamers or antibodies that bind the target of interest. More specifically, the invention relates to an electrochemical-based read out of a sensing mechanism that uses a nucleic acid-based proximity assay in conjunction with a pair of aptamers or antibodies for sample quantification. The biosensor or a set of biosensors can be used either as a standalone measurement system for a single analyte target or as a component of a multiplexed cartridge for multiple analytes.

Described herein are nucleic acid-based electrochemical proximity assays (ECPAs) for sample quantification. The invention may also include a biosensor with a sensing mechanism that uses a pair of aptamers or antibodies that bind the target of interest. More specifically, the invention relates to an electrochemical-based read out of a sensing mechanism that uses a nucleic acid-based proximity assay in conjunction with a pair of aptamers or antibodies for sample quantification. The biosensor or a set of biosensors can be used either as a standalone measurement system for a single analyte target or as a component of a multiplexed cartridge for multiple analytes.

Described herein are nucleic acid-based electrochemical proximity assays (ECPAs) for sample quantification. The invention may also include a biosensor with a sensing mechanism that uses a pair of aptamers or antibodies that bind the target of interest. More specifically, the invention relates to an electrochemical-based read out of a sensing mechanism that uses a nucleic acid-based proximity assay in conjunction with a pair of aptamers or antibodies for sample quantification. The biosensor or a set of biosensors can be used either as a standalone measurement system for a single analyte target or as a component of a multiplexed cartridge for multiple analytes.

Detection of viral nucleic acids (NAs) and their variants is effected using nanopore technology. If the target wild type viral NA is single-stranded, it is mixed with its complementary NA, and also the unknown viral NA sample to be analyzed, followed by hybridization; while if the target wild type viral NA is double-stranded, it is mixed with the unknown viral NA sample only, then denatured and followed by hybridization. The hybridized products from either case are then subjected to translocation in the form of a translocation analysis, experiment or test through a nanopore device that measures the electrical signals induced through translocation events. The corresponding signal train is characteristic of an individual virus or variant and acts as a “fingerprint” facilitating rapid virus identification and discovery of a new variant.

Detection of viral nucleic acids (NAs) and their variants is effected using nanopore technology. If the target wild type viral NA is single-stranded, it is mixed with its complementary NA, and also the unknown viral NA sample to be analyzed, followed by hybridization; while if the target wild type viral NA is double-stranded, it is mixed with the unknown viral NA sample only, then denatured and followed by hybridization. The hybridized products from either case are then subjected to translocation in the form of a translocation analysis, experiment or test through a nanopore device that measures the electrical signals induced through translocation events. The corresponding signal train is characteristic of an individual virus or variant and acts as a “fingerprint” facilitating rapid virus identification and discovery of a new variant.